MiNK Therapeutics (NASDAQ:INKT) Releases Earnings Results, Misses Estimates By $0.02 EPS

MiNK Therapeutics (NASDAQ:INKT) released its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02), Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK advanced agenT-797 into a randomized Phase II ARDS study, with enrollment continuing in Ukraine and U.S. sites expected to begin enrolling in September. The company expects preliminary randomized data in the first half of 2027 and is preparing to discuss a potential seamless Phase III design with the FDA.
• Initial observations from two treated patients showed survival without fever at day 28, improved oxygenation, ARDS resolution, spontaneous breathing, vasopressor liberation, infection control, and no major treatment-related serious adverse events. However, management emphasized that the data are early, non-comparative, and based on a small run-in cohort.
• MiNK launched its first international paid named-patient access program in Brazil, generating physician-directed access and payments while building cross-border logistics and regulatory infrastructure. The company said additional patients were treated after quarter-end and that further financial details are expected with its third-quarter update.
• MiNK ended the quarter with $8.8 million in cash, down from $9.5 million at the end of the first quarter, while quarterly operating cash use increased to $2.1 million as the Phase II trial was operationalized. The company continues to report losses and did not provide explicit cash-runway guidance.

MiNK Therapeutics Stock Up 2.5%

Shares of NASDAQ:INKT traded up $0.27 during trading on Friday, hitting $11.27. 6,786 shares of the stock traded hands, compared to its average volume of 9,526. The company has a market cap of $56.12 million, a price-to-earnings ratio of -4.70 and a beta of 0.48. The company has a fifty day moving average price of $11.33 and a two-hundred day moving average price of $11.23. MiNK Therapeutics has a 52-week low of $8.48 and a 52-week high of $18.17.

Key Headlines Impacting MiNK Therapeutics

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: MiNK reported encouraging early observations from a randomized Phase 2 trial evaluating agenT-797 in acute lung injury, including potential activity in patients with severe respiratory disease. The update supports continued interest in the company’s off-the-shelf iNKT cell therapy platform. MiNK second-quarter results and agenT-797 trial update
• Positive Sentiment: The company said U.S. enrollment in its acute respiratory distress syndrome (ARDS) program is expected to begin in September, with participating sites projected to enroll approximately four to eight patients per month. A defined enrollment pace could improve visibility into the program’s clinical timeline. MiNK ARDS enrollment update
• Positive Sentiment: Management emphasized agenT-797’s early promise during its second-quarter earnings call, keeping the clinical program as the primary potential catalyst for the stock. MiNK Q2 2026 earnings call highlights
• Neutral Sentiment: MiNK remains a clinical-stage biotechnology company, so valuation is heavily dependent on future trial results and financing needs rather than current revenue or profits. The company’s earnings call provided additional program detail but did not establish commercial validation. MiNK Q2 2026 earnings call summary
• Negative Sentiment: MiNK reported a second-quarter loss of $0.62 per share, slightly worse than the $0.60 analyst consensus, underscoring its ongoing cash-burn risk. MiNK quarterly earnings report
• Negative Sentiment: Zacks Research downgraded MiNK from “strong buy” to “hold,” potentially limiting buying interest despite the clinical updates. Zacks Research

Analyst Ratings Changes

Several brokerages have issued reports on INKT. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of MiNK Therapeutics in a research note on Monday, May 18th. Zacks Research lowered MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, Weiss Ratings upgraded MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $35.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC raised its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.